EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Investigating the Effectiveness of Brexpiprazole in Subjects with Schizophrenia Spectrum Illness and Co-Occurring Substance Use Disorder: A Prospective, Multicentric, Real-World Study

Stefania Chiappini iD, Clara Cavallotto iD, Alessio Mosca iD, Francesco Di Carlo iD, Tommaso Piro, Giulia Giovannetti iD, Arianna Pasino iD, Mariachiara Vicinelli, Chiara Lorenzini, Mariapia Di Paolo, Maria Pepe, Marco Di Nicola iD und 3 weitere

Pharmaceuticals · 21.04.2024 · 17 (4) · 535

DOI: 10.3390/ph17040535 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 21.04.2024. Verfasst von Stefania Chiappini und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, UniCamillus International Medical School University, Via di S. Alessandro 8, 00131 Rome, Italy. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dual disorders (DDs) involve the coexistence of a substance use disorder (SUD) with another mental illness, often from the psychotic and affective categories. They are quite common in clinical practice and present significant challenges for both diagnosis and treatment. This study explores the effectiveness of brexpiprazole, a third-generation antipsychotic, in an Italian sample of individuals diagnosed with schizophrenia spectrum disorder and a comorbid SUD.

Methods

Twenty-four patients, diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) and enrolled in several Italian hospitals, underwent a psychometric assessment at baseline (T0) and one month (T1) after starting brexpiprazole treatment administered at a mean dosage of 2 mg/day.

Results

Brexpiprazole demonstrated significant reductions in psychopathological burden (Positive and Negative Syndrome Scale/PANSS total score: p < 0.001). Positive (p = 0.003) and negative (p = 0.028) symptoms, substance cravings (VAS craving: p = 0.039), and aggression (MOAS scale: p = 0.003) were notably reduced. Quality of life improved according to the 36-item Short Form Health Survey (SF-36) subscales (p < 0.005).

Conclusions

This study provides initial evidence supporting brexpiprazole’s efficacy and safety in this complex patient population, with positive effects not only on psychopathology and quality of life, but also on cravings. Further studies involving larger cohorts of subjects and extended follow-up periods are needed.

Schlagwörter

Stichwörter der Autor:innen

addictionbrexpiprazoledual disordersreal-world studysubstance use disordersubstance-induced psychosis

Autor:innen und Institutionen

  • School of Medicine, UniCamillus International Medical School University, Via di S. Alessandro 8, 00131 Rome, Italy.
  • Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, 66100 Chieti, Italy.
  • University Polyclinic Foundation "A. Gemelli" IRCCS, Catholic University of the Sacred Heart, 00136 Rome, Italy.
  • Department of Psychiatry, "San Luigi Gonzaga" Hospital, University of Turin, 10124 Turin, Italy.

ORCID-Profile: Stefania Chiappini, Clara Cavallotto, Alessio Mosca, Francesco Di Carlo, Giulia Giovannetti, Arianna Pasino, Marco Di Nicola, Valerio Ricci, Mauro Pettorruso, Giovanni Martinotti

Zitieren

APA

Chiappini, S., Cavallotto, C., Mosca, A., Di Carlo, F., Piro, T., Giovannetti, G., Pasino, A., Vicinelli, M., Lorenzini, C., Di Paolo, M., Pepe, M., Di Nicola, M., Ricci, V., Pettorruso, M., & Martinotti, G. (2024). Investigating the Effectiveness of Brexpiprazole in Subjects with Schizophrenia Spectrum Illness and Co-Occurring Substance Use Disorder: A Prospective, Multicentric, Real-World Study. Pharmaceuticals, 17(4), 535. https://doi.org/10.3390/ph17040535

Vancouver

Chiappini S, Cavallotto C, Mosca A, Di Carlo F, Piro T, Giovannetti G, et al. Investigating the Effectiveness of Brexpiprazole in Subjects with Schizophrenia Spectrum Illness and Co-Occurring Substance Use Disorder: A Prospective, Multicentric, Real-World Study. Pharmaceuticals. 2024;17(4):535. doi:10.3390/ph17040535

BibTeX
@article{Chiappini2024,
  author = {Chiappini, Stefania and Cavallotto, Clara and Mosca, Alessio and Di Carlo, Francesco and Piro, Tommaso and Giovannetti, Giulia and Pasino, Arianna and Vicinelli, Mariachiara and Lorenzini, Chiara and Di Paolo, Mariapia and Pepe, Maria and Di Nicola, Marco and Ricci, Valerio and Pettorruso, Mauro and Martinotti, Giovanni},
  title = {Investigating the Effectiveness of Brexpiprazole in Subjects with Schizophrenia Spectrum Illness and Co-Occurring Substance Use Disorder: A Prospective, Multicentric, Real-World Study},
  journal = {Pharmaceuticals},
  year = {2024},
  volume = {17},
  number = {4},
  pages = {535},
  doi = {10.3390/ph17040535}
}
Kostenlos starten →